cure for cancer...you can invest, page-34

I've run some numbers to see what the veterinary side of things could potentially be earning in the next couple of years while human trials are ongoing.

- The $10mill was raised giving 208,333,334 shares.

- From the OIS there are a total of 220,511 incidences of treatable cancer (with EBC-46) in Australia per year. The drug will only be available in Australia in the next couple of years so I'm limiting just to Aussie.

- Assuming in the first year (2011) 5% of the total of the above cases are treated with EBC-46, increasing by 10% increments of the total cases annually.

- Assuming there's about $300 profit per treatment (I believe this is ballpark figure)

Year 1 (5% cases treated) - EPS = $0.016 , Total Profit = $3,307,665
Year 2 (15% cases treated) - EPS = $0.032 , Total Profit = $6,615,330
Year 3 (25% cases treated) - EPS = $0.048 , Total Profit = $9,922,995

Say we use this and a conservative P/E = 5 (considering unlisted, high risk, etc) to estimate a market cap for the Veterinary side of the company we get:

Year 1 = $16,538,325
Year 2 = $33,076,650
Year 3 = $49,614,975

So any comments?

I think the veterinary market in Australia has great earning potential. Ecobiotics owns 84% of Qbiotics so this should also be taken into consideration.